ADPT
Adaptive Biotechnologies Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 107 | 0 | 115.13M | $2.47B | +6 | −6 |
| Q1 2026 | 110 | +7 | 111.61M | $1.55B | +11 | −4 |
| Q4 2025 | 102 | 0 | 114.72M | $1.86B | +1 | −1 |
| Q3 2025 | 21 | +2 | 74.70M | $1.12B | +2 | — |
| Q2 2025 | 16 | +2 | 70.34M | $819.50M | +2 | — |
| Q1 2025 | 11 | 0 | 46.91M | $348.49M | +2 | −2 |
| Q4 2024 | 11 | -1 | 53.01M | $317.80M | — | −1 |
| Q3 2024 | 11 | +2 | 55.08M | $282.02M | +2 | — |
| Q2 2024 | 9 | — | 54.39M | $196.88M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 29.99M | — | $108.58M | 0.4% | n/c | 1 | SEC ↗ |
| 2 | ARK Investment Management ✦ | 11.41M | — | $41.31M | 0.4% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 9.26M | — | $33.53M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.68M | — | $9.71M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 402.12K | — | $1.46M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 182.08K | — | $635,445 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | T. Rowe Price ✦ | 158.81K | — | $575,000 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 151.80K | — | $549,516 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | PRIMECAP Management ✦ | 146.19K | — | $529,208 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 295 holders, 151.59M shares, $2.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.88K sh · $304,866
Officer · 11.88K sh · $313,658
Officer · 1.10K sh · $31,031
Officer · 9.38K sh · $256,664
Officer · 6.44K sh · $193,320
Officer · 499 sh · $15,234
Officer · 901 sh · $26,769
Officer · 6.70K sh · $193,065
Officer · 5.18K sh · $153,750
Officer · 11.88K sh · $334,213
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology